ViiV Healthcare has received positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending expanded use of Tivicay and Dovato in younger children living with HIV across the EU.
The recommendations are aimed at addressing ongoing treatment gaps in paediatric HIV care. According to ViiV, only 55% of children living with HIV globally received antiretroviral therapy in 2024, while around half of untreated infants with HIV die before reaching two years of age.
The CHMP recommended extending the indication for Tivicay (dolutegravir) dispersible tablets for use in HIV-infected adults, adolescents, children and term neonates from birth weighing at least 2kg when used with other antiretroviral medicines.
If approved, ViiV said Tivicay would become the first second-generation integrase inhibitor available in the EU for eligible newborns.
The committee also recommended approval of a new dispersible tablet formulation of Dovato (dolutegravir/lamivudine) for children aged at least three months and weighing between 6kg and less than 25kg. An extension to the existing film-coated tablet indication for children weighing at least 20kg was also recommended.
If approved, Dovato could become the first single-tablet, two-drug treatment option for eligible younger children living with HIV in the EU.
Jean van Wyk, Chief Medical Officer at ViiV Healthcare, said: “Children living with HIV require lifelong care, making continued innovation essential. If approved, Tivicay would become the first second-generation integrase inhibitor to offer eligible newborns dolutegravir-based treatment, while Dovato would bring the first single tablet, two-drug regimen option to eligible younger children.”
He added: “These positive CHMP opinions mark an important step towards expanding age-appropriate, INSTI-based treatment options for children and advancing our goal of offering greater choice in HIV care, so more people living with HIV can benefit from innovative treatment options at every stage of life.”
The applications were supported by data from the IMPAACT 2023, Penta-21 and DANCE studies. European Commission decisions are expected in the first quarter of 2027.










